Rajiv Agarwal

Professor of Medicine

Indiana State University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Rajiv Agarwal is a Professor of Medicine at Indiana University, USA. His research primarily focuses on the intersection of cardio-kidney-metabolic syndrome, chronic kidney disease (CKD), and diabetes management. Recent articles highlight his work on combination therapies, implementation of global guidelines, and the impact of specific receptor agonists in CKD patients.

Articles (27)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (17)

Guillermo Umpierrez

Professor of Medicine

Emory University School of Medicine

UNITED STATES

Rajiv Agarwal

Research Interests

Explore related searches

Contact this professor

About

Articles (27)

Impact of Baseline GLP-1 Receptor Agonist Use on Albuminuria Reduction and Safety With Simultaneous Initiation of Finerenone and Empagliflozin in Type 2 Diabetes and Chronic Kidney Disease (CONFIDENCE Trial)

Impact of Simultaneous Initiation of Finerenone and Empagliflozin on Urinary Albumin-to-Creatinine Ratio in Asia

Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations

Implementation of Established Global Guidelines in the Management of CKD in Patients with Type 2 Diabetes in Asia

Author Correction: Chronic kidney disease

Building CONFIDENCE in Upfront Combination Therapy Across Cardio-Kidney-Metabolic Syndrome

Tailoring Sodium Restriction to Genetic Susceptibility

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes

COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics

Steroidal or nonsteroidal mineralocorticoid receptor antagonists for reducing cardiovascular burden in chronic kidney disease

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD

Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

George L. Bakris, MD (1952 to 2024)

Mechanisms of antihypertensive effect of chlorthalidone in advanced chronic kidney disease—a causal mediation analysis

Cardiovascular Benefits of Potassium-Enriched Salt Substitution: Promises and Challenges of Secondary Analyses

Resistant Hypertension in Dialysis: Epidemiology, Diagnosis, and Management

The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

Hypertension in chronic kidney disease—treatment standard 2023

Cover Image

Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline

Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease

Should we CLICK on chlorthalidone for treatment-resistant hypertension in chronic kidney disease?

The Author Replies

The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature

The Nonsteroidal Mineralocorticoid-Receptor-Antagonists Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Collaborators (17)

Guillermo Umpierrez

Hiddo Lambers Heerspink

Ele Ferrannini

Clare Arnott

David M. Charytan

Jennifer Green

Motoko Yanagita

Robert Toto

Gian Luca Di Tanna

Hans-Joachim Anders

Patrick Rockenschaub

Brendon Neuen

george bakris

Kaitlin Mayne

Aletta Schutte

Janet McGill

William Herrington

Make your next move.